Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | BPTF | Q12830 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30926135 | 0.80 | SMN1; SMN2 (0.39) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13116644 | 0.70 | HTR3A (0.55) | PLD1ADRB1ALDH1A1HTR3EHTR3B | |
| SCHEMBL2351496 | 0.69 | KDM4E (0.46) | PLD1ADRB2KDM4EALDH1A1NCF1 | |
| SCHEMBL15219342 | 0.69 | SIGMAR1 (0.41) | ALDH1A1SIGMAR1TDP1 | |
| SCHEMBL30926130 | 0.68 | SMN1; SMN2 (0.36) | KDM4EALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL26633214 | 0.68 | KDM4E (0.48) | PLD1ADRB2KDM4EALDH1A1NCF1 | |
| SCHEMBL14356019 | 0.68 | HTR1A (0.47) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL10646244 | 0.67 | NCF1 (0.40) | ADRB1ADRB2KDM4ENCF1HRH4 | |
| SCHEMBL15219340 | 0.67 | SIGMAR1 (0.44) | ALDH1A1HRH4SIGMAR1SMN1; SMN2 | |
| SCHEMBL11636479 | 0.67 | ADRB2 (0.38) | PLD1ADRB2KDM4EALDH1A1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079983-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079985-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079984-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4301468-B1 | FGFR3 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4565576-A1 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | Boehringer Ingelheim International GmbH (DE) | 2025-06-11 | — | — | EP | disclosed |
| EP-4558492-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| CN-119654315-A | 3- (6-Pyridin-3-yl) -2- [4- (4-methyl-4H-1, 2, 4-triazol-3-yl) piperidin-1-yl ] benzonitrile derivatives and similar compounds as QPCTL and QPCT inhibitors for the treatment of cancer | 858治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119630655-A | Piperidinyl pyridyl carbonitrile derivatives as inhibitors of glutamyl peptide cyclotransferase and glutamyl peptide cyclotransferase-like proteins | 勃林格殷格翰国际有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12209086-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| US-11878976-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-01-23 | — | — | US | disclosed |
| EP-4301468-A1 | FGFR3 INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117120439-A | FGFR3 inhibitor compounds | 伊莱利利公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220389003-A1 | 4-SUBSTITUTED INDOLE AND INDAZOLE SULFONAMIDO DERIVATIVES AS PARG INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022187443-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4031249-A1 | 4-SUBSTITUTED INDOLE AND INDAZOLE SULFONAMIDO DERIVATIVES AS PARG INHIBITORS | Ideaya Biosciences, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021055744-A1 | 4-SUBSTITUTED INDOLE AND INDAZOLE SULFONAMIDO DERIVATIVES AS PARG INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-4613601-A | (1-benzodioxin-6-ylmethyl)-4-substituted piperazines having antipsychotic activity | ADIR, S.A.R.L. (FR) | 1986-09-23 | — | — | US | disclosed |
| US-4177272-A | HYPOTENSIVE, VASODILATION, PARKINSON'S DISEASE | SCIENCE UNION ET CIE (FR) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878976-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | PLD1 4228/4885ADRB1 2825/4885ADRB2 4168/4885 |
| US-12209086-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | PLD1 4228/4885ADRB1 2825/4885ADRB2 4168/4885 |
| US-20220389003-A1 | 4-SUBSTITUTED INDOLE AND INDAZOLE SULFONAMIDO DERIVATIVES AS PARG INHIBITORS | PARG, PARP11, PARN | PLD1 3719/4885ADRB1 1784/4885ADRB2 2414/4885 |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | PLD1 4228/4885ADRB1 2825/4885ADRB2 4168/4885 |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | PLD1 4228/4885ADRB1 2825/4885ADRB2 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.